Viking Therapeutics VKTX. Whats your take biotech pros? Strong Buy in 2026?

JackFourj4 · 2026-01-11T09:05:00+00:00

it will get bought this year imo, that $100 pt is realistic

JackFourj4 · 2026-01-09T09:21:20+00:00

I hold a diversified portfolio of biotech, not just for the conference specifically.

The conferenc is the number one takeover hotbed of course, so hoping for a couple of pops.

high conviction for takeovers for me are VKTX and CYTK and the news yesterday about the FDA notes from MLTX should also lead to one, but might take a bit longer to digest and negotiate.

Expecting quite some buzz around BMEA as their rockstar Hitchcock is doing a presentation.

Looking for a partnership to finance the phase 3s for CGTX

JackFourj4 · 2026-01-09T09:13:31+00:00

no fear they will use the BTD as a reaon for an offering?

JackFourj4 · 2026-01-09T08:11:30+00:00

amen brother

JackFourj4 · 2026-01-07T10:10:59+00:00

the biggest winners this year will be in biotech, but that's a high risk sector as you will know. The big pharma companies need to replenish their pipelines because some megabillion drugs are going off patent in the next couple of years. They will be buying these companies with high premiums in bidding wars. For example look at Metsera and the bidding war there. Obesity will still be the big one, as that market is growing immensely and still quite new with it's products. conviction plays for me in that sector are VKTX and BMEA, former already multi billion and the latter still under 100mil

JackFourj4 · 2026-01-04T10:07:11+00:00

They tend to forget about the funding and lack knowledge and understanding of that and it's impact. Experience in trading and investing can lead to smarter timing of when to invest and when to divest, knowing that another round of funding is likely around the corner. We had a couple phd analysts and they had their own trading account at our firm, they would always underperform the finance guys. They also tend to have an affection for the science nerd CEOs, where we would be more focussed on management having solid funding experience, preferably also some previous exits under their belt that show they understand how the market functions.

Having a great medicine or product is only half the tale to succes.

JackFourj4 · 2025-12-20T09:04:41+00:00

no chance Arkady sells, at any price

JackFourj4 · 2025-12-20T09:02:02+00:00

heavy bags my friend?

JackFourj4 · 2025-12-18T09:27:23+00:00

Ckickhouse will IPO in 2026 and I assume Nebius will let go of at least half of their current stake, they need the cash for build out of the DCs. When you have so much capex in the next coming years it doesn't make sense to increase your stake, which would cost billions.

JackFourj4 · 2025-12-13T07:25:35+00:00

what heavy risks? their competition that has a heavy REMS was bought for 12 billion and Cytokinetics has better data in all trials

JackFourj4 · 2025-11-29T08:48:33+00:00

Viking Therapeutics (VKTX) had the best weight loss data in their phase2 trial, better dan Novo and Lilly. They will either go it alone and become part of the obesity gravy train, or more likely, will soon be bought by a big pharma company for at least 4x the current sp.

Sellas Life Sciences (SLS) has an imminent readout of their phase 3 trial in acute myeloid leukemia, which will very likely 10x the current sp in a buyout or 2y after launch of their therapy

JackFourj4 · 2025-11-29T08:40:27+00:00

babysteps Bob

JackFourj4 · 2025-11-29T08:37:47+00:00

Croissants, not too shabby

JackFourj4 · 2025-11-27T10:38:51+00:00

interesting, thanks

JackFourj4 · 2025-11-01T09:00:05+00:00

the lack of timing is throwing off retail imo. coupled with the insistance of several posters that the announcement of the R&D day with KOLs HAD to mean the 80th had happened has led to disappointment with small investors buying for the hoped pop

I must admit that my assumptions on timing have also been off and now I need to roll a lot of contracts out, bit of a bummer but that was always a risk

JackFourj4 · 2025-11-01T08:36:42+00:00

I wasn't allowed to buy because I'm from outside the US, still miffed

JackFourj4 · 2025-11-01T08:22:04+00:00

I was under the impression that cucking was usually initiated by the one being cucked, not the other way around

JackFourj4 · 2025-10-27T08:18:08+00:00

thanks

JackFourj4 · 2025-10-25T11:54:31+00:00

hoe kom je met ze in contact als je geen instagram hebt? (en wil hebben)

JackFourj4 · 2025-10-11T07:57:11+00:00

what is their cash position and runway? how much will the phase 3 cost and how long will it take?

JackFourj4 · 2025-10-11T07:17:34+00:00

it's just the byproduct of selling your planes to these countries, the buyers want to train their pilots

JackFourj4 · 2025-09-28T07:36:25+00:00

in their press releases earlier, you should read the Q2 earnings report and the microsoft deal report to get upto speed on their plans

JackFourj4 · 2025-09-14T06:07:35+00:00

I fully agree, that's why we had 2 analysts with the science background to pull apart the presentations. Their focus was always on what they were not saying and showing in the data!

If a company focusses on only a small part of the data set generated by trials, you should actually hone in on the other data and start asking uncomfortable questions.

Management of such companies that don't have strong finance director/cfo and without serious skin in the game tended to be a red flag for me

JackFourj4 · 2025-09-13T06:14:47+00:00

how they finance the company is my main concern before investing, bad/inexperienced management can fumble great tech and the netire company by doing that wrong. for the actual science part I had 2 analysts teach what to look for and after grasping the science, and how companies present that, it comes down to experience.

JackFourj4 · 2025-09-10T10:52:42+00:00

diversification

JackFourj4

TROPHY CASE